Literature DB >> 23453243

Low-dose high-dose-rate brachytherapy in the treatment of facial lesions of cutaneous T-cell lymphoma.

Jennifer A DeSimone1, Emmanuella Guenova, Joi B Carter, Keri S Chaney, Julie R Aldridge, Claire M Noell, Andrew A Dorosario, Jorgen L Hansen, Thomas S Kupper, Phillip M Devlin.   

Abstract

BACKGROUND: The use of many of the standard skin-directed mycosis fungoides (MF) therapies on facial skin may be limited by site-specific increased risks of side effects, excessive inflammation, and ocular toxicity.
OBJECTIVE: Our study aimed to describe the levels of erythema, scale, and induration of facial lesions in MF before and after low-dose high-dose-rate surface applicator brachytherapy and to examine the overall clinical response to brachytherapy.
METHODS: A total of 23 facial MF lesions in 10 patients were treated with high-dose-rate brachytherapy doses of 4 Gy per session for a total of 2 fractions at our multidisciplinary cutaneous oncology clinic between August 17, 2009, and March 12, 2012.
RESULTS: In all 23 lesions, dramatic clinical improvement was observed. Patients were followed up for a median of 6.3 months. No recurrences were reported in the follow-up period. LIMITATIONS: Long-term follow-up is lacking. Reassessment of all included patients at annual intervals for a period of at least 5 years is the authors' goal.
CONCLUSION: Low-dose high-dose-rate brachytherapy using custom-made surface molds is a highly efficacious therapy in the treatment of facial lesions in MF.
Copyright © 2013 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23453243     DOI: 10.1016/j.jaad.2012.12.975

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  8 in total

1.  Development of a method for treating lower-eyelid carcinomas using superficial high dose rate brachytherapy.

Authors:  H Stephens; C Deans; D Schlect; T Kairn
Journal:  Phys Eng Sci Med       Date:  2020-10-29

2.  Radiotherapy Eradicates Malignant T Cells and Is Associated with Improved Survival in Early-Stage Mycosis Fungoides.

Authors:  John T O'Malley; Adele de Masson; Elizabeth L Lowry; Anita Giobbie-Hurder; Nicole R LeBoeuf; Cecilia Larocca; Ahmed Gehad; Edward Seger; Jessica E Teague; David C Fisher; Thomas S Kupper; Phillip M Devlin; Rachael A Clark
Journal:  Clin Cancer Res       Date:  2019-10-21       Impact factor: 12.531

3.  Epigenetically Enhanced PDT Induces Significantly Higher Levels of Multiple Extrinsic Pathway Apoptotic Factors than Standard PDT, Resulting in Greater Extrinsic and Overall Apoptosis of Cutaneous T-cell Lymphoma.

Authors:  Katrin A Salva; Youn H Kim; Ziba Rahbar; Gary S Wood
Journal:  Photochem Photobiol       Date:  2018-05-20       Impact factor: 3.421

4.  Mycosis fungoides and Sézary syndrome.

Authors:  Constanze Jonak; Julia Tittes; Patrick Manfred Brunner; Emmanuella Guenova
Journal:  J Dtsch Dermatol Ges       Date:  2021-09       Impact factor: 5.231

5.  High-dose-rate brachytherapy of primary cutaneous B-cell lymphoma: the first reported case series.

Authors:  Artur J Chyrek; Grzegorz M Bielȩda; Wojciech M Burchardt; Adam Chicheł
Journal:  J Contemp Brachytherapy       Date:  2020-06-30

6.  Extensive Cutaneous T-Cell Lymphoma of the Feet Treated with High-Dose-Rate Brachytherapy and External Beam Radiation.

Authors:  Joy Tao; Courtney Hentz; Michael L Mysz; Issra Rashed; David Eilers; James Swan; Rebecca Tung; Bahman Emami
Journal:  Case Rep Dermatol Med       Date:  2018-08-07

7.  Increased Chlormethine-Induced DNA Double-Stranded Breaks in Malignant T Cells from Mycosis Fungoides Skin Lesions.

Authors:  Yun-Tsan Chang; Desislava Ignatova; Wolfram Hoetzenecker; Steve Pascolo; Christina Fassnacht; Emmanuella Guenova
Journal:  JID Innov       Date:  2021-11-25

8.  Mould-based surface high-dose-rate brachytherapy for eyelid carcinoma.

Authors:  Andrea Vavassori; Giulia Riva; Stefano Durante; Cristiana Fodor; Stefania Comi; Raffaella Cambria; Federica Cattani; Giuseppe Spadola; Roberto Orecchia; Barbara Alicja Jereczek-Fossa
Journal:  J Contemp Brachytherapy       Date:  2019-10-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.